Skip to main content
British Medical Journal logoLink to British Medical Journal
. 1974 Dec 14;4(5945):617–621. doi: 10.1136/bmj.4.5945.617

Gonadotrophin-releasing Hormone Therapy in Hypogonadal Males with Hypothalamic or Pituitary Dysfunction

C H Mortimer, A S McNeilly, R A Fisher, M A F Murray, G M Besser
PMCID: PMC1612996  PMID: 4613417

Abstract

Subcutaneous self-administration of synthetic gonadotrophin-releasing hormone 500 μg eight-hourly for up to one year by 12 male patients (five prepubertal) with clinical hypogonadism due to hypothalamic or pituitary disease resulted in the synthesis and continued release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). There was a rise in circulating androgen levels in all patients. Improvements in pubertal ratings were seen in some prepubertal patients. Potency returned in the adults and spermatogenesis was induced and maintained in the four patients who had received treatment for more than four months, total counts reaching between 7·8 and 432 × 106 spermatozoa. A fall in the FSH response to the releasing hormone occurred during spermatogenesis though LH was little affected. During the initial weeks of therapy FSH secretion usually occurred before that of LH though LH secretion was greater as treatment continued. FSH secretion also persisted for longer when treatment was stopped.

Full text

PDF
617

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. August G. P., Tkachuk M., Grumbach M. M. Plasma testosterone-binding affinity and testosterone in umbilical cord plasma, late pregnancy, prepubertal children, and adults. J Clin Endocrinol Metab. 1969 Jul;29(7):891–899. doi: 10.1210/jcem-29-7-891. [DOI] [PubMed] [Google Scholar]
  2. Forest M. G., Bertrand J. Studies of the protein binding of dihydrotestosterone (17-beta-hydroxy-5 alpha-androstan-3 one) in human plasma (in different physiological conditions and effect of medroxyprogesterone) (17-hydroxy-6 alpha-methyl-4 pregnene-3,20 dione 17-acetate). Steroids. 1972 Feb;19(2):197–214. doi: 10.1016/0039-128x(72)90005-0. [DOI] [PubMed] [Google Scholar]
  3. Franchimont P., Becker H., Ernould C., Thys C., Demoulin A., Bourguignon J. P., Legros J. J., Valcke J. C. The effect of hypothalamic luteinizing hormone releasing hormone (LH-RH) on plasma gonadotrophin levels in normal subjects. Clin Endocrinol (Oxf) 1974 Jan;3(1):27–39. doi: 10.1111/j.1365-2265.1974.tb03293.x. [DOI] [PubMed] [Google Scholar]
  4. Hotchkiss J., Atkinson L. E., Knobil E. Time course of serum estrogen and luteinizing hormone (LH) concentrations during the menstrual cycle of the rhesus monkey. Endocrinology. 1971 Jul;89(1):177–183. doi: 10.1210/endo-89-1-177. [DOI] [PubMed] [Google Scholar]
  5. Moss R. L., McCann S. M. Induction of mating behavior in rats by luteinizing hormone-releasing factor. Science. 1973 Jul 13;181(4095):177–179. doi: 10.1126/science.181.4095.177. [DOI] [PubMed] [Google Scholar]
  6. Pfaff D. W. Luteinizing hormone-releasing factor potentiates lordosis behavior in hypophysectomized ovariectomized female rats. Science. 1973 Dec 14;182(4117):1148–1149. doi: 10.1126/science.182.4117.1148. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES